Courtesy of Sigma-Aldrich
Most commercially available reagents for RNAi are synthetic oligos, which can yield good results with immortalized cell lines but are less effective in hard-to-transfect primary cells. To address this problem, The RNAi Consortium (TRC), comprising 10 biomedical research institutions, recently began the commercial rollout of its MISSION TRC shRNA library.
St. Louis-based Sigma-Aldrich
"The advantages of a viral system are twofold," says Keith Joliff, manager of global strategic marketing at Sigma-Aldrich. "It allows the insertion of the shRNA into the genome of the cell, so you get a permanent phenotype ... [and] it allows you to get the DNA into cell lines that do not transfect...